Pharmaceutical
Technology
Health

Titan Pharmaceuticals

$1.34
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-4.96%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell TTNP and other stocks, options, ETFs, and crypto commission-free!

About

Titan Pharmaceuticals, Inc. Common Stock, also called Titan Pharmaceuticals, is a biopharmaceutical company, which engages in development of therapeutics for the treatment of medical disorders. Read More Its products include Probuphine, Ropinirole Implant, and T3 Implant. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.

Employees
23
Headquarters
South San Francisco, California
Founded
1992
Market Cap
104.60M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
806.91K
High Today
$1.43
Low Today
$1.31
Open Price
$1.41
Volume
125.66K
52 Week High
$6.90
52 Week Low
$1.03

Collections

Pharmaceutical
Technology
Health
Biopharmaceutical
Therapy
Medical
US
North America

News

Seeking AlphaMay 15

Titan Pharmaceuticals, Inc. CEO Sunil Bhonsle on Q1 2019 Results - Earnings Call Transcript

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Q1 2019 Results Earnings Conference Call May 15, 2019 4:30 PM ET Company Participants Sunil Bhonsle - President and CEO Marc Rubin - Executive Chairman Kate DeVarney - EVP and Chief Scientific Officer Dane Hallberg - EVP and Chief Commercial Officer Brian Crowley - VP, Finance Jennifer Kiernan - IR Conference Call Participants Ben Haynor - Alliance Global Partners Anita Dushyanth - Zacks Small-Cap Research Deepankar Roy - Brookline Capital Markets. Opera...

626
Yahoo FinanceMay 13

Titan Pharmaceuticals Further Expands Patient Access To Probuphine® Via Product Purchase And Supply Agreement With Express Scripts' Specialty Pharmacy, Accredo®

SOUTH SAN FRANCISCO, Calif., May 13, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced that it has executed a product purchase and supply agreement with Accredo specialty pharmacy, a subsidiary of Express Scripts, further expanding access to treatment with Probuphine (buprenorphine) implant, Titan's novel maintenance treatment for Opioid Use Disorder (OUD) in eligible patients. Titan Pharmaceuticals, Inc. (PRNewsfoto/Titan Pharmaceuticals, Inc.) More Titan expects the majority of Pro...

697
Markets InsiderMay 9

Titan Pharmaceuticals To Release First Quarter 2019 Financial Results On May 15 - Conference Call To Follow

649

Earnings

-$0.34
-$0.24
-$0.14
-$0.04
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.26 per share
Actual
-$0.34 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.